Abstract
Blood loss and bleeding tendency with the consequence of homologous blood transfusion still present a major problem in cardiac surgery. Many efforts have been made to influence the bleeding tendency in open-heart surgery by pharmacological means. Aprotinin is a naturally occurring enzyme inhibitor derived from bovine lungs. It acts on trypsin, plasmin, tissue-kallikrein and, to lesser degree, on plasma-kallikrein [1, 2]. Moreover, it is reported to have direct platelet-preserving properties in very high dosages [3]. Aprotinin has been used in Europe for a long time in varying indications, but only since the results published by Royston et al. [4] who applied very high dosages of aprotinin, has this drug been regarded with increased interest. Recently, these results were corroborated by several studies [5–9].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Emerson FE (1989) Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovasc Drug Rev 7: 127–140
Fritz H (1985) The target enzymes of aprotinin in vitro and in vivo. Proteolyse und Proteinaseinhibition in der Herz- und Gefäßchirurgie, 143–154
Aoki N, Naito K, Yoshida N (1978) Inhibition of platelet aggregation by protease inhibitors. Possible involvement of proteases in platelet aggregation. Blood 52: 1–12
Royston D, Taylor KM, Bidstrup BP, Sapsford RN (1987) Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet: ii 1289–1291
Alajmo F, Calamai G, Perna AM et al (1989) High-Dose Aprotinin: Hemostatic effects in openheart operations. Ann Thorac Surg 48: 536–539
Bidstrup BP, Royston D, Sapsfort RN, Taylor KM (1989) Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97: 364–372
Dietrich W, Barankay A, Dilthey G, et al (1989) Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application — clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surgeon 37: 92–98
Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V (1989) Reduction of blood transfusion requirement in open-heart surgery by administration of high doses of aprotinin — preliminary results. Thorac Cardiovasc Surgeon 37: 89–91
van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH (1990) Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99: 788–797
Edmunds LH, Ellison N, Colman WR, et al (1982) Platelet function during cardiac operation — comparison of membran and bubble oxygenators. J Thorac Cardiovasc Surg 83: 805–812
Harker LA (1986) Bleeding after cardiopulmonary bypass. N Engl J Med 314: 446–448
Bauer KA, Rosenberger RD (1984) Thrombin generation in acute promyelocytic leukemia. Blood 64: 64
Müller-Esterl W, Oettl A, Trucheit E, Fritz H (1984) Monitoring of aprotinin plasma levels by an enzyme-linked immunosorbent assay (ELISA). Fresenius Z Anal Chem 317: 718
Wendt P, Fritsch A, Schulz F, Wunderlich G, Blümel G (1984) Proteinases and inhibitors in plasma and peritoneal exudate in acute pankreatitis. Hepato-gastroenterol 31: 277–281
van Oeveren W, Jansen NJG, Bidstrup BP, et al (1987) Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 44: 640–645
Henze R, Dietrich W, Hähnel C, Sebening F, Richter JA (1989) Verminderter Blutverbrauch in der Herzchirurgie durch intraoperative Aprotininapplikation. Anästhesist 38: 510
Dietrich W, Spannagl M, Jochum M, Wendt P, Sebening F, Richter JA (1989) Reduction of homologous blood requirement in cardiac surgery using high-dose aprotinin. Anesthesiology (Suppl)
Dietrich W, Hähnel C, Richter JA (1990) Routine application of high-dose aprotinin in openheart surgery — a study on 1784 patients. Anesthesiology (Suppl), in press
Edmunds LH (1989) Letter to the editor: Blood platelets and bypass. J Thorac Cardiovasc Surg 97: 470–477
Colman RW (1984) Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 73: 1249–1253
Carvalho AC, De Marinis S, Scott CF, Silver LD, Schmaier AH, Colman RW (1988) Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 112: 270–277
Verstraete M (1985) Clinical application of inhibitors of fibrinolysis. Drugs 29: 236–261
Hattersley PG (1966) Activated coagulation time of whole blood. JAMA 196: 436–440
Fritz H, Wunderer G, (1983) Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim Forsch/Drug Res 33: 479–494
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dietrich, W., Spannagl, M., Jochum, M., Wendt, P., Barankay, A., Richter, J.A. (1991). Investigation on the Mechanisms of Action of Aprotinin in Cardiac Surgery. In: Friedel, N., Hetzer, R., Royston, D. (eds) Blood Use in Cardiac Surgery. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-662-06119-0_37
Download citation
DOI: https://doi.org/10.1007/978-3-662-06119-0_37
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-662-06121-3
Online ISBN: 978-3-662-06119-0
eBook Packages: Springer Book Archive